To enhance the submission process for new drugs and biological products, Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) has developed a dedicated a dedicated Screening Package. This initiative aims to provide clearer guidance and promote Good Submission Practice by helping applicants ensure their dossiers are complete and meet regulatory requirements before submission.
Malaysia announces Screening Package for new drugs and biologicals
Home/Policies & Legislation
|
Posted 25/08/2025
0
Post your comment
The Screening Package was introduced during the Good Regulatory Practice Workshop on 16 April 2025 and took effect on 16 June 2025. From this date onward, all applications must include a complete screening package.
Key mandatory components of the Screening Package include:
- A cover letter
- A screening checklist
- Applicant Declaration on Post-Marketing Commitments
- Asean Common Technical Dossier (ACTD) Part III: Non-Clinical Documentation – Good Laboratory Practice (GLP) Compliance Form
- Bioequivalence Study Report Submission Checklist
The NPRA has published a detailed guidance to assist industry stakeholders with applications and the screening process [1].
Malaysia has a well-established biosimilars approval pathway, with guidance first published in 2008 that was based on the European Medicines Agency’s framework [2].
In 2024, the NPRA announced trialled new timelines for variation applications of registered pharmaceutical products and traditional and natural health supplements (TMHS) to improve efficiency in post-approval changes [3]. The new Screening Package is expected to further streamline the drug approval process in Malaysia.
Related articles
Duopharma to establish Malaysia’s first commercial biosimilar facility
PanGen gains Malaysian approval for epoetin alfa biosimilar
|
LATIN AMERICAN FORUM View the latest headline article: El ‘One Big Beautiful Bill’ de Trump: implicaciones para la sanidad estadounidense Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO Ver el último artículo de cabecera: El ‘One Big Beautiful Bill’ de Trump: implicaciones para la sanidad estadounidense !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. |
References
1. GUIDANCE FOR REGISTRATION APPLICATION FOR NEW DRUG PRODUCTS AND BIOLOGICS, CENTRE OF PRODUCT AND COSMETIC EVALUATION NATIONAL PHARMACEUTICAL REGULATORY AGENCY. Version 1.0, May 2025. Available from: https://www.npra.gov.my/images/2019/12/NCE/ScreeningPackage/GUIDANCE_FOR_REGISTRATION_APPLICATION_FOR_NEW_DRUG_PRODUCTS_AND_BIOLOGICS.pdf
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars regulation, clinical trials, approval and adverse events in Malaysia [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Aug 25]. Available from: www.gabionline.net/biosimilars/research/Biosimilars-regulation-clinical-trials-approval-and-adverse-events-in-Malaysia
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2025 Pro Pharma Communications International. All Rights Reserved.
Source: NPRA, Ministry of Health Malaysia
Guidelines
Swissmedic aligns biosimilar guidance with EMA’s tailored clinical approach
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Reports
China edges past US in novel cancer approvals as Chinese biosimilars expand
Central America moves toward joint evaluation of biosimilar medicines
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
ANVISA updates understanding on biosimilar interchangeability
China's 12th VBP round accelerates shift to generics and biosimilars dual-track
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Home/Policies & Legislation Posted 15/09/2026
Congress pushes biosimilar bills as interchangeability concerns linger
Home/Policies & Legislation Posted 02/09/2026
ANVISA updates understanding on biosimilar interchangeability
Home/Policies & Legislation Posted 22/07/2026
China's 12th VBP round accelerates shift to generics and biosimilars dual-track
Home/Policies & Legislation Posted 03/07/2026
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment